Morgane Longo ♾

AI is no longer a promise for healthcare — it’s happening now. From the France Healthcare Innovation Summit to real-world impact, the transformation is underway. 🔹 Personalized treatment plans powered by AI 🔹 Faster, smarter care in underserved areas 🔹 Patients empowered with real-time insights 🔹 Specialized AI models that reduce costs and boost outcomes 🔗Read more on this article by Lucas Najun Dubos MD MSc MBA: https://lnkd.in/dDgEswZ9 #AIinHealthcare

146

2 commentaires

Over the past few days, you may have seen it : an open letter, signed by 30+ startups and organizations across Europe, calling for a unified evaluation framework for Digital Medical Devices (DMDs). And I can only stand behind it. Why? Because Europe has a single market for medical devices… but 27 different national frameworks to evaluate, reimburse, and make them accessible to patients. Today, a digital medical device can be clinically validated, CE-certified, interoperable… and yet still blocked in its deployment. At Okeiro, we build ready-to-use, validated tools to transform patient care. But between Germany, France, Italy, or the Netherlands, the rules change, the doors close, and the timelines explode. The result: 📉 Solutions ready but underused ⏳ Patients left waiting 🩺 And in the meantime, healthcare professionals forced to make do with what they have This is not a question of innovation. Nor of scientific evidence. It’s a question of political will and a common framework. I am proud to sign this open letter as CEO of Okeiro, to support a simple yet essential proposal : A unified European evaluation framework for DMDs, starting in 2026, based on shared clinical and technical criteria. I invite you to read and sign this letter to make European sovereignty in digital health possible (link in comments to sign). https://lnkd.in/eiPbjSyM And to share it in support of a coherent, open, and strong European ecosystem 🇪🇺 . France Biotech France Digitale MedTech in France Spitzenverband Digitale Gesundheitsversorgung Ministère de la Santé Bundesministerium für Gesundheit European Commission EIT Health Tilak Healthcare Kranus Health HelloBetter Anne-Aurélie Epis de Fleurian Edouard Gasser Thilo Kleinschmidt, MBA Hannes Klöpper Daphne Petrich Charlotte Puechmaille

67

1 commentaire

Let’s break taboos and build solutions: #Biocodex joins forces with Femtech France. We are proud to join the leading collective uniting more than 80 French startups committed to transforming the future of women’s health. ➡️ This collaboration marks a new milestone in our innovation strategy, focused on long-overlooked needs. #Endometriosis, #PremenstrualSyndrome, #Menopause — these intimate health topics remain underserved. At Biocodex, we believe #WomensHealth deserves sustained and collective action. By joining Femtech France, we are combining: 👉 our scientific expertise — particularly in vaginal microbiota,  👉 our ability to collaborate with ecosystem players,  👉 and our support for innovation, through initiatives such as the Microbiota & Women’s Health International Grant (Biocodex Microbiota Foundation) and the partnership between #Saforelle and My S Life.  ️ “By working directly with startups that address real needs expressed by women themselves, we can accelerate the development of truly transformative solutions.”  — Nicolas COUDURIER, CEO of Biocodex Together, let’s make women’s health a driver of progress.  

78

4 commentaires

JEITO's Founder and CEO Rafaèle Tordjman was on BFM Business last week to discuss why we made a significant participation in the $213M Series D round of Odyssey Therapeutics. A few key reasons behind this investment ⤵️ 1️⃣ A potential meaningful patient-benefit for millions of patients suffering from autoimmune and inflammatory diseases, notably inflammatory bowel diseases 2️⃣ A strong interest from major pharmaceutical companies seeking therapeutic innovations that addresses large populations with still high unmet needs make a real difference for patients. 3️⃣ A strong positioning of Jeito in this significant (>$200M) and competitive series D that reflects our expertise in this high potential therapeutic area illustrated through our portfolio exit of Hi-Bio, acquired by Biogen for $1.8B. Watch the full interview here 👉 https://lnkd.in/e4nUjFCf  #FasterForThePatient #PrivateEquity #LifeSciences #Biopharma #AutoimmuneDisease

65

RAISE Impact is proud to announce its investment in Happyneuron, a leading cognitive‑assessment and rehabilitation platform, alongside the company’s leadership team ✨ Founded by digital‑health experts, Happyneuron runs on a solid SaaS model: - 40+ clinically validated modules - 10,000+ speech‑language therapists already on board - Growing adoption by hospitals, neuropsychologists and other clinicians By offering in‑depth assessments and targeted remediation tools across key cognitive functions (hearing, language, adult neurology, numerical cognition, and more), the platform helps practitioners deliver greater precision, efficiency and patient reach 🧠 With the support of RAISE Impact, the Group aims to scale its solutions to an ever‑larger community of healthcare professionals and to accelerate its international expansion 🌎 Learn more ▶️ https://lnkd.in/exPUcmjY Edouard Blanchard, Aglaé Touchard Le Drian, Serge Bedrossian, Alexandre Cordel, Ludovico Buongarzone, Charlotte Colson #impact #healthtech

113

3 commentaires

💰 Solence  has raised €1.6 million in seed funding to develop AI-driven digital therapeutics for polycystic ovary syndrome (PCOS), a condition affecting up to 20% of women globally. Impact Shakers Ventures led the round, with participation from notable angel investors including Celine Lazorthes (founder of Leetchi, Mangopay and Resilience), former JP Morgan executive Berthe Latreille, Systemanova.vc founder Stephane Mardel, and Bpifrance. 🤝 💬 “PCOS is one of the great blind spots in women’s healthcare. It’s time to change that. Ultimately, our vision is to leverage data and environmental factors to better address chronic hormonal conditions among women, with a focus on prevention and improving their healthy life expectancy.” Clara Stephenson, Solence Founder & CEO 👉 Full Story: https://lnkd.in/g65nAA2U #femtech #womenshealth #womenshealthinnovation #healthcare #healthtech #digitalhealth #healthcareinnovation #pcos #hormonehealth #digitaltherapeutics #investment #startup #investor #vc #venturecapital

89

11 commentaires

📢 Caresyntax is proud to support CHU de Rennes in integrating our video-management solution into their operating rooms 🏥🔬 With the upcoming opening of the new Interventional Surgery Center, CHU Rennes is adopting cutting-edge digital solutions to enhance patient safety, optimize surgical workflows, and support clinical decision-making. 📊💡 This marks the beginning of a long-term partnership dedicated to empowering surgical teams with data-driven insights to manage risk and improve outcomes. We are proud to partner with CHU de Rennes and in collaboration with our partner Relyens en France to provide surgical teams with the tools they need to enhance efficiency and patient safety from day one.🚀🏥 Bjoern von Siemens Amel Mokrani Bois Julie Rambahiniarison Julien Isman David Dupeyron CHU de Rennes Relyens en France #PatientSafety #Innovation #HealthcareTechnology #CHUdeRennes

125

2 commentaires

[#POLYGRAMPodcast] 🎧 The new episode of the Health Series is out: 𝘾𝙖𝙣 𝙣𝙚𝙬 𝙩𝙚𝙘𝙝𝙣𝙤𝙡𝙤𝙜𝙮 𝙝𝙚𝙡𝙥 𝙩𝙝𝙚 𝙖𝙜𝙞𝙣𝙜 𝙥𝙤𝙥𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝙡𝙞𝙫𝙚 𝙡𝙤𝙣𝙜𝙚𝙧 𝙖𝙣𝙙 𝙗𝙚𝙩𝙩𝙚𝙧? 👵 🎙️ Meet Jérôme BOUDY, researcher at SAMOVAR* laboratory - Télécom SudParis and project partner at E-Vita, a startup offering #innovative digital health solutions for older adults. 💡 He explains how #technology can support healthy #aging and ease the strain on #healthcare systems #worldwide. 🔬 Supported by the Engineering for Health (E4H) center, this series highlights IP Paris’ cutting-edge research addressing major medical and societal challenges: from prosthetics and antimicrobial resistance to surgical innovations, transplant algorithms, and cancer research. ➡️ Discover the new episode here: https://lnkd.in/eAYKRGuh #IPParis #InstitutPolytechniquedeParis #E4H #IPParisResearch #IPParisInnovation #Health #Santé #Aging #DigitalHealth #Podcast École Polytechnique ENSTA École nationale des ponts et chaussées ENSAE Paris Télécom Paris *SAMOVAR: a research lab Télécom SudParis, Institut Polytechnique de Paris, 91120 Palaiseau, France

30

ArcaScience, a French AI Healthtech startup innovating benefit-risk evaluation to make better, safer drugs, has announced a €6 million Seed funding round to accelerate the clinical impact of its AI 🇫🇷 🏥 The round was led by The Moon Venture, with participation from Pleiade Venture, Plug and Play Tech Center, Bpifrance, and AKKA Technologies. “It takes 10+ years to bring a drug to market. There is a 90% fail rate and the average cost per drug that makes it to the market is $2.3 billion! Benefit-risk prediction is no longer a nice-to-have, but a prerequisite for building better drugs. This funding round will help us scale our product, and bring real benefit-risk clarity to both the pharma industry and patients,” said Romain CLEMENT, Founder and CEO at ArcaScience. Read here: https://lnkd.in/dW4cwvPa

71

10 commentaires